Key result
Statin therapy in the elderly requires a collaborative decision balancing cardiovascular benefits with potential risks such as polypharmacy, side effects, and cognitive limitations.
Why the study?
Does statin therapy provide a favorable risk-benefit profile for secondary prevention in elderly patients?
Does statin therapy provide a favorable risk-benefit profile for secondary prevention in elderly patients?
Statin therapy in the elderly requires a collaborative, patient-focused approach balancing cardiovascular benefits against risks like polypharmacy and side effects.
No takes yet. Share an insight, caveat, or question.
Supports high-intensity statins in >65-year-olds; extends scarce RCT evidence beyond 2013 guidelines.
Wilmot et al. (2014) conducted a review in Cardiovascular risk. Statins was evaluated. Statin therapy in the elderly requires a collaborative decision balancing cardiovascular benefits with potential risks such as polypharmacy, side effects, and cognitive limitations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: